Title

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors.

Division

East Florida

Hospital

JFK - MU

Document Type

Abstract

Publication Date

1-1-2021

Keywords

empagliflozin, diabetes mellitus, pancreatitis, drug-related side effects and adverse reactions

Disciplines

Endocrine System Diseases | Gastroenterology

Abstract

Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tract infections among others. We present a case of severe epigastric abdominal pain consistent with acute pancreatitis in the setting of empagliflozin use, suggesting a possible drug-induced acute pancreatitis.

Publisher or Conference

ACG Case Reports Journal

Share

COinS